BACKGROUND: Skeletal muscle wasting and dysfunction are strong independent predictors of mortality in patients with chronic obstructive pulmonary disease (COPD). Creatine nutritional supplementation produces increased muscle mass and exercise performance in health. A controlled study was performed to look for similar effects in 38 patients with COPD. METHODS:Thirty eight patients with COPD (mean (SD) forced expiratory volume in 1 second (FEV(1)) 46 (15)% predicted) were randomised to receive placebo (glucose polymer 40.7 g) or creatine (creatine monohydrate 5.7 g, glucose 35 g) supplements in a double blind trial. After 2 weeks loading (one dose three times daily), patients participated in an outpatient pulmonary rehabilitation programme combined with maintenance (once daily) supplementation. Pulmonary function, body composition, and exercise performance (peripheral muscle strength and endurance, shuttle walking, cycle ergometry) took place at baseline (n = 38), post loading (n = 36), and post rehabilitation (n = 25). RESULTS: No difference was found in whole body exercise performance between the groups: for example, incremental shuttle walk distance mean -23.1 m (95% CI -71.7 to 25.5) post loading and -21.5 m (95% CI -90.6 to 47.7) post rehabilitation. Creatine increased fat-free mass by 1.09 kg (95% CI 0.43 to 1.74) post loading and 1.62 kg (95% CI 0.47 to 2.77) post rehabilitation. Peripheral muscle performance improved: knee extensor strength 4.2 N.m (95% CI 1.4 to 7.1) and endurance 411.1 J (95% CI 129.9 to 692.4) post loading, knee extensor strength 7.3 N.m (95% CI 0.69 to 13.92) and endurance 854.3 J (95% CI 131.3 to 1577.4) post rehabilitation. Creatine improved health status between baseline and post rehabilitation (St George's Respiratory Questionnaire total score -7.7 (95% CI -14.9 to -0.5)). CONCLUSIONS:Creatine supplementation led to increases in fat-free mass, peripheral muscle strength and endurance, health status, but not exercise capacity. Creatine may constitute a new ergogenic treatment in COPD.
RCT Entities:
BACKGROUND: Skeletal muscle wasting and dysfunction are strong independent predictors of mortality in patients with chronic obstructive pulmonary disease (COPD). Creatine nutritional supplementation produces increased muscle mass and exercise performance in health. A controlled study was performed to look for similar effects in 38 patients with COPD. METHODS: Thirty eight patients with COPD (mean (SD) forced expiratory volume in 1 second (FEV(1)) 46 (15)% predicted) were randomised to receive placebo (glucose polymer 40.7 g) or creatine (creatine monohydrate 5.7 g, glucose 35 g) supplements in a double blind trial. After 2 weeks loading (one dose three times daily), patients participated in an outpatient pulmonary rehabilitation programme combined with maintenance (once daily) supplementation. Pulmonary function, body composition, and exercise performance (peripheral muscle strength and endurance, shuttle walking, cycle ergometry) took place at baseline (n = 38), post loading (n = 36), and post rehabilitation (n = 25). RESULTS: No difference was found in whole body exercise performance between the groups: for example, incremental shuttle walk distance mean -23.1 m (95% CI -71.7 to 25.5) post loading and -21.5 m (95% CI -90.6 to 47.7) post rehabilitation. Creatine increased fat-free mass by 1.09 kg (95% CI 0.43 to 1.74) post loading and 1.62 kg (95% CI 0.47 to 2.77) post rehabilitation. Peripheral muscle performance improved: knee extensor strength 4.2 N.m (95% CI 1.4 to 7.1) and endurance 411.1 J (95% CI 129.9 to 692.4) post loading, knee extensor strength 7.3 N.m (95% CI 0.69 to 13.92) and endurance 854.3 J (95% CI 131.3 to 1577.4) post rehabilitation. Creatine improved health status between baseline and post rehabilitation (St George's Respiratory Questionnaire total score -7.7 (95% CI -14.9 to -0.5)). CONCLUSIONS:Creatine supplementation led to increases in fat-free mass, peripheral muscle strength and endurance, health status, but not exercise capacity. Creatine may constitute a new ergogenic treatment in COPD.
Authors: Jeffrey Weisberg; Jack Wanger; Jeffery Olson; Barry Streit; Charles Fogarty; Thomas Martin; Richard Casaburi Journal: Chest Date: 2002-04 Impact factor: 9.410
Authors: Karine Marquis; Richard Debigaré; Yves Lacasse; Pierre LeBlanc; Jean Jobin; Guy Carrier; François Maltais Journal: Am J Respir Crit Care Med Date: 2002-09-15 Impact factor: 21.405
Authors: P Hespel; B Op't Eijnde; M Van Leemputte; B Ursø; P L Greenhaff; V Labarque; S Dymarkowski; P Van Hecke; E A Richter Journal: J Physiol Date: 2001-10-15 Impact factor: 5.182
Authors: Liam P Kilduff; Jonathan P Fuld; J Alberto Neder; Yannis P Pitsiladis; Roger Carter; Robin Stevenson; Susan A Ward Journal: Respiration Date: 2003 Nov-Dec Impact factor: 3.580
Authors: Liam P Kilduff; Petar Vidakovic; Gerard Cooney; Richard Twycross-Lewis; Paul Amuna; Matt Parker; Lorna Paul; Yannis P Pitsiladis Journal: Med Sci Sports Exerc Date: 2002-07 Impact factor: 5.411
Authors: Paola S Cella; Poliana C Marinello; Fernando H Borges; Diogo F Ribeiro; Patrícia Chimin; Mayra T J Testa; Philippe B Guirro; José A Duarte; Rubens Cecchini; Flávia A Guarnier; Rafael Deminice Journal: Eur J Nutr Date: 2019-02-26 Impact factor: 5.614
Authors: François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner Journal: Am J Respir Crit Care Med Date: 2014-05-01 Impact factor: 21.405
Authors: Michael Kingsley; Daniel Cunningham; Laura Mason; Liam P Kilduff; Jane McEneny Journal: Oxid Med Cell Longev Date: 2009 Sep-Oct Impact factor: 6.543
Authors: A Jatoi; P D Steen; P J Atherton; D F Moore; K M Rowland; N A Le-Lindqwister; C S Adonizio; A J Jaslowski; J Sloan; C Loprinzi Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Gun Faager; Karin Söderlund; Carl Magnus Sköld; Siw Rundgren; Anna Tollbäck; Per Jakobsson Journal: Int J Chron Obstruct Pulmon Dis Date: 2006